AMRX - Amneal Pharma down 5% premarket on Q2 miss and guidance cut August, 05 2019 09:25 AM Amneal Pharmaceuticals Inc. Class A Amneal Pharmaceuticals (AMRX) Q2 results: Revenues: $404.6M (-2.2%).More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...